MINDY4 and lung carcinoma: Moreover, the analysis of the lung cancer patients dataset from cBioPortal [21] demonstrated that the median overall survival was 42.31 months with FAM188B alteration (n = 300), whereas it was 60.12 months without FAM188B alteration (n = 213) (p = 0.0140) (Figure 7C).